Winer et al
Winer et al. demonstrate that gain-of-function (i.e., activating) mutations in IL7R and NRAS cooperate to drive T-cell acute lymphoblastic leukemia (T-ALL) in mice mainly due to the ability to activate MYC, in particular via NRAS-dependent up-regulation of MYC protein levels. NRAS likely promotes MYC protein stabilization by at least two mechanisms: directly, by phosphorylation of MYC, and indirectly, via transcriptional activation of PLK-1, whose increased expression prevents MYC proteasomal degradation. Bcl-2 is also up-regulated (essentially due to IL7R-mediated signaling), although its exact role in the cooperative oncogenic effects of IL7R and NRAS is unclear. The use of a chemical inhibitor of PLK-1 (volasertib) or of a drug that down-regulates MYC (and IL7R) transcription (JQ-1) diminishes leukemia burden in vivo. Pre-clinical studies evaluating the value of these drugs against human T-ALL with IL7R and RAS signaling pathway mutations are warranted. Final version by somersault18:24
Publication
Anatomy of a crime: how IL7R and NRAS join forces to drive T-cell acute lymphoblastic leukemia (2024) João T. Barata, et al. Haematologica. 2024 Jun 01;109(6). Figure: F1.| Organism | Group | Word | Match | Source | NCBI Symbol | NCBI ID |
|---|
| Word | Match | MeSH | Name | ChEBI |
|---|
Disease mentions
| Word | Match | MeSH | Name | DOID |
|---|